Drug Approval | March 27, 2024
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Hepatitis B infects over 40 million people in India
Pharma Solutions operates 10 research and development and/or production sites globally
The pilot plant is focused on scaling up beverage production and will support applications
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
More than 10,000 scientific publications containing EUDRAGIT
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Anand is committed to leading the company's continued commitment to driving innovation in Health Care through the utilization of Digital transformation, AI and LLM
It is the first autotaxin inhibitor to be investigated in cancer patients
Subscribe To Our Newsletter & Stay Updated
